# Batoclimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/batoclimab

> Batoclimab, sponsored by Immunovant, Inc. (IMVT): 10 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | batoclimab |
| Codes | IMVT-1401 |
| Sponsor | Immunovant, Inc. (IMVT) https://sec-api.dev/companies/imvt/catalysts |
| Indications | active, moderate-to-severe thyroid eye disease, [thyroid eye disease](https://sec-api.dev/indications/thyroid-eye-disease), [Chronic Inflammatory Demyelinating Polyneuropathy](https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy) |
| Modality | antibody |
| FDA designations | orphan |

## Timeline

### June 30, 2022: trial start

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2025-02-06, last confirmed 2025-02-06.
- SEC Form 10-Q (accession 0001764013-25-000026): "In the quarter ended June 30, 2022, we initiated our Phase 3 pivotal trial of batoclimab as a treatment for MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm

### December 31, 2022: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-02-06, last confirmed 2025-02-06.
- SEC Form 10-Q (accession 0001764013-25-000026): "In the quarter ended December 31, 2022, we initiated a pivotal Phase 2b trial of batoclimab as a treatment for CIDP." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm

### March 31, 2025: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 3.
- First seen 2024-11-12, last confirmed 2025-05-29.
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000024): "Immunovant intends to report top-line results from the pivotal trial of batoclimab in MG by March 31, 2025." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm
- SEC Form 10-Q (accession 0001764013-25-000026): "Enrollment in this pivotal trial was completed in the quarter ended September 30, 2024, and we expect top-line data to be available by March 31, 2025." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm
- SEC Form 10-Q (accession 0001764013-25-000026): "We expect to report top-line data from the Phase 3 trial of batoclimab for the treatment of MG by March 31, 2025, with potential registrational development for MG expected to transition from batoclimab to IMVT-1402 in the same timeframe." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000024): "•Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025" https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm
- SEC Form 10-K (accession 0001764013-25-000092): "In March 2025, we announced top-line results of our Phase 3 study of batoclimab in MG, which met its primary endpoint of change in the Myasthenia Gravis Activities of Daily Living ("MG-ADL") score from baseline in acetylcholine receptor antibody positive ("AChR+") patients." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-24-046015): "Topline data from the batoclimab trial in MG is expected by March 31, 2025." https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-003639): "Batoclimab topline results from pivotal trial in myasthenia gravis (MG) and initial results from period 1 of trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025" https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/ef20043151_ex99-1.htm
- SEC Form 10-K (accession 0001140361-25-020715): "In March 2025, we announced top-line results of our Phase 3 study of batoclimab in MG, which met its primary endpoint of change in the Myasthenia Gravis" https://www.sec.gov/Archives/edgar/data/1635088/000114036125020715/ef20047582_10k.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: thyroid eye disease.
- First seen 2024-11-12, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000024): "Top-line results from the pivotal program of batoclimab for the treatment of thyroid eye disease (TED), also known as Graves' ophthalmopathy, continue to be expected in the second half of calendar year 2025, along with a decision whether to pursue marketing authorization for batoclimab in TED." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm
- SEC Form 10-Q (accession 0001764013-25-000129): "We expect to report topline data from our Phase 3 trials of batoclimab in thyroid eye disease in the second half of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000129/imvt-20250630.htm
- SEC Form 10-Q (accession 0001764013-25-000026): "The trial is ongoing with top-line results estimated to be available in the second half of calendar year 2025, along with a decision on whether to advance batoclimab to registration in TED." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm
- SEC Form 10-Q (accession 0001764013-25-000129): "We plan to report top-line results from this clinical trial in the second half of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000129/imvt-20250630.htm
- SEC Form 10-K (accession 0001764013-25-000092): "We plan to report top-line results from this clinical trial in the second half of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001846253-25-000053): "Additionally, top-line results for batoclimab from potentially registrational Phase 3 trials in thyroid eye disease are expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/a2025q1ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-24-046015): "Topline data from the current pivotal program evaluating batoclimab in thyroid eye disease (TED) now expected in the second half of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_ex99-1.htm

### November 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05517421 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT05517421

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-10, last confirmed 2026-02-06.
- SEC Form 8-K (accession 0001193125-25-314994): "However, due to evolving competitive dynamics, we anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000148): "However, due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concurrently in the first half of calendar year 2026" https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000148): "However, due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm
- SEC Form 10-Q (accession 0001764013-26-000011): "We anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm
- SEC prospectus (424B) (accession 0001193125-25-316765): "However, due to evolving competitive dynamics, we anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000119312525316765/d47651d424b5.htm
- SEC Form 10-Q (accession 0001764013-25-000149): "However, due to evolving competitive dynamics, we anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000149/imvt-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000010): "Immunovant anticipates sharing topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate to severe thyroid eye disease (TED) in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm
- SEC Form 10-Q (accession 0001764013-26-000011): "We continue to anticipate sharing top-line results from the two batoclimab Phase 3 TED studies concurrently in the first half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm

### February 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05524571 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT05524571

### Apr 2026: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3. Indication: active, moderate-to-severe thyroid eye disease.
- First seen 2026-05-20, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000062): "In April 2026, we announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease (TED), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In April 2026, we announced top-line results from two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease ("TED"), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In April 2026, we announced top-line results from two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease ("TED"), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001635088-26-000060): "In April 2026, we announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease (TED), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/q4fy2025roivantearningsrel.htm
- SEC Form 10-K (accession 0001635088-26-000061): "In April 2026, we announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease ("TED"), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm
- SEC Form 10-K (accession 0001635088-26-000061): "•In April 2026, we announced top-line results from two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease ("TED"), neither of which met the primary endpoint." https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm

### April 2, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05517447 (Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT05517447

### July 16, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Chronic Inflammatory Demyelinating Polyneuropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07188844 (An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT07188844

## Same indication

- [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) (IMVT)
- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)
- [Empasiprubart](https://sec-api.dev/pdufa/empasiprubart) (ARGX)
- [Empasiprubart iv](https://sec-api.dev/pdufa/empasiprubart-iv) (ARGX)
- [Imeroprubart](https://sec-api.dev/pdufa/imeroprubart) (IMVT)
- [Riliprubart](https://sec-api.dev/pdufa/riliprubart) (SNY)
- [Lumvoa™ (veligrotug)](https://sec-api.dev/pdufa/veligrotug) (VRDN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/batoclimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Batoclimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/batoclimab

```bibtex
@misc{secapidev_pdufa_batoclimab_20261116,
  title        = {Batoclimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/batoclimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_batoclimab_20261116","title":"Batoclimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/batoclimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
